WO2008057599A3 - Methods for the treatment of abeta related disorders and compositions therefor - Google Patents

Methods for the treatment of abeta related disorders and compositions therefor Download PDF

Info

Publication number
WO2008057599A3
WO2008057599A3 PCT/US2007/023663 US2007023663W WO2008057599A3 WO 2008057599 A3 WO2008057599 A3 WO 2008057599A3 US 2007023663 W US2007023663 W US 2007023663W WO 2008057599 A3 WO2008057599 A3 WO 2008057599A3
Authority
WO
WIPO (PCT)
Prior art keywords
related disorders
treatment
methods
compositions therefor
abeta related
Prior art date
Application number
PCT/US2007/023663
Other languages
French (fr)
Other versions
WO2008057599A2 (en
Inventor
Lawrence P Wennogle
Original Assignee
Intra Cellular Therapies Inc
Lawrence P Wennogle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc, Lawrence P Wennogle filed Critical Intra Cellular Therapies Inc
Publication of WO2008057599A2 publication Critical patent/WO2008057599A2/en
Publication of WO2008057599A3 publication Critical patent/WO2008057599A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

The invention provides methods for treating Aβ peptide related disorders such as Alzheimer's disease comprising administering to a patient in need thereof a substituted 2-(pyrimidinylamino)-thiazole-5-carboxamides in free or pharmaceutically acceptable salt form, preferably dasatinib, in an amount effective to inhibit or reduce accumulation of Aβ peptide.
PCT/US2007/023663 2006-11-10 2007-11-09 Methods for the treatment of abeta related disorders and compositions therefor WO2008057599A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85833006P 2006-11-10 2006-11-10
US60/858,330 2006-11-10

Publications (2)

Publication Number Publication Date
WO2008057599A2 WO2008057599A2 (en) 2008-05-15
WO2008057599A3 true WO2008057599A3 (en) 2008-12-18

Family

ID=39365146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/023663 WO2008057599A2 (en) 2006-11-10 2007-11-09 Methods for the treatment of abeta related disorders and compositions therefor

Country Status (1)

Country Link
WO (1) WO2008057599A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2461673A4 (en) 2009-08-05 2013-08-07 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
NZ704666A (en) 2012-08-23 2018-05-25 Alios Biopharma Inc Compounds for the treatment of paramoxyvirus viral infections
CN105030776A (en) * 2015-06-24 2015-11-11 北京键凯科技有限公司 Application of Src protein inhibitor to preparation of medicine used for preventing and/or treating Alzheimer's disease
WO2023059867A1 (en) * 2021-10-08 2023-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for treating or preventing alzheimer's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103107A1 (en) * 2004-06-21 2008-05-01 Malcolm Ward Screening Methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103107A1 (en) * 2004-06-21 2008-05-01 Malcolm Ward Screening Methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCDONALD D.R.: "Amyloid Fibrils Activate Tyrosine Kinase-dependent signaling and Superoxide Production in Microglia", THE JOURNAL OF NEUROSCIENCE, vol. 17, no. 7, 1 April 1997 (1997-04-01), pages 2284 - 2294, XP002669072 *
NAM S.: "Action of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells", CANCER RESEARCH, vol. 65, no. 20, 2005, pages 9185 - 9189, XP002425076 *

Also Published As

Publication number Publication date
WO2008057599A2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2007012061A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
PT2527315E (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease
MX2009005279A (en) N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's.
WO2008103472A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2008097538A8 (en) Therapeutic agents
EP2331095A4 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2006020581A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
WO2007087151A3 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
IL188752A0 (en) Pharmaceutical compositions comprising a tungsten salt (vi) for the treatment of neurodegenerative disorders, particularly alzheimer's disease and schizophrenia
WO2008066626A3 (en) METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2002100818A3 (en) Aminediols as agents for the treatment of alzheimer's disease
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2008135661A3 (en) Use of citrulline for the treatment of conditions linked to an increase in protein carbonylation
HK1110211A1 (en)
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
WO2007034329A3 (en) Compounds and methods for treatment of amyloid-beta-peptide related disorders
PT1778837E (en) Treatment of neurodegenerative diseases by the use of scd4 inhibitors
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO2006029487A8 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867405

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07867405

Country of ref document: EP

Kind code of ref document: A2